<DOC>
	<DOCNO>NCT01134835</DOCNO>
	<brief_summary>To test hypothesis stimulation PPAR-γ receptor therapeutic role treatment asthma .</brief_summary>
	<brief_title>PPAR-gamma : Novel Therapeutic Target Asthma ?</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Age 1875 either sex clinical diagnosis asthma , FEV1 ≥ 60 % predicted increase FEV1 great 12 % follow inhaled salbutamol 400μg Peak Expiratory Flow ( PEF ) variability &gt; 12 % runin . Allowed medication : 0800μg inhale beclomethasone diproprionate equivalent require short act beta agonist . Current smoking , &gt; 10 pack year smoke history , Treatment leukotriene antagonist , Liver cardiovascular disease , Oral steroid treatment exacerbation within 6 week , Females pregnant , lactate use adequate contraception , Any contraindication pioglitazone ( hypersensitivity pioglitazone , cardiac failure , history cardiac failure , hepatic impairment , diabetic ketoacidosis ) , Oral insulin treatment diabetes , Treatment gemfibrozil rifampicin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>